Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BIBW 2992 versus cetuximab in platinum-failed recurrent or metastatic head and neck squamous cell carcinoma
2008-007097-38Phase 2Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jan 2009
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in head and neck squamous cell carcinoma (HNSCC) comparing BIBW 2992 with Erbitux (2 arms). Primary endpoint: Tumor shrinkage before cross-over. Started Jan 2009; status: completed.
02
Drugs
afatinibcetuximab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on 2008-007097-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-007097-38.